Logo image of ATHA

ATHIRA PHARMA INC (ATHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ATHA - US04746L2034 - Common Stock

3.87 USD
-0.08 (-2.03%)
Last: 12/12/2025, 8:14:43 PM
3.87 USD
0 (0%)
After Hours: 12/12/2025, 8:14:43 PM
Fundamental Rating

2

Taking everything into account, ATHA scores 2 out of 10 in our fundamental rating. ATHA was compared to 191 industry peers in the Pharmaceuticals industry. While ATHA seems to be doing ok healthwise, there are quite some concerns on its profitability. ATHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATHA has reported negative net income.
ATHA had a negative operating cash flow in the past year.
In the past 5 years ATHA always reported negative net income.
In the past 5 years ATHA always reported negative operating cash flow.
ATHA Yearly Net Income VS EBIT VS OCF VS FCFATHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ATHA has a worse Return On Assets (-125.61%) than 82.72% of its industry peers.
ATHA has a worse Return On Equity (-140.83%) than 68.59% of its industry peers.
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROIC N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ATHA Yearly ROA, ROE, ROICATHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ATHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHA Yearly Profit, Operating, Gross MarginsATHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

ATHA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ATHA has been increased compared to 5 years ago.
There is no outstanding debt for ATHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATHA Yearly Shares OutstandingATHA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ATHA Yearly Total Debt VS Total AssetsATHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ATHA has an Altman-Z score of -20.52. This is a bad value and indicates that ATHA is not financially healthy and even has some risk of bankruptcy.
ATHA has a Altman-Z score of -20.52. This is amonst the worse of the industry: ATHA underperforms 85.86% of its industry peers.
There is no outstanding debt for ATHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.52
ROIC/WACCN/A
WACCN/A
ATHA Yearly LT Debt VS Equity VS FCFATHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ATHA has a Current Ratio of 9.70. This indicates that ATHA is financially healthy and has no problem in meeting its short term obligations.
ATHA has a better Current ratio (9.70) than 79.06% of its industry peers.
A Quick Ratio of 9.70 indicates that ATHA has no problem at all paying its short term obligations.
ATHA has a better Quick ratio (9.70) than 79.06% of its industry peers.
Industry RankSector Rank
Current Ratio 9.7
Quick Ratio 9.7
ATHA Yearly Current Assets VS Current LiabilitesATHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.04% over the past year.
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.82% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.83%
EPS Next 2Y34.35%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATHA Yearly Revenue VS EstimatesATHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 10K 20K 30K 40K 50K
ATHA Yearly EPS VS EstimatesATHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHA Price Earnings VS Forward Price EarningsATHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHA Per share dataATHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ATHA's earnings are expected to grow with 25.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.35%
EPS Next 3Y25.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATHA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ATHIRA PHARMA INC

NASDAQ:ATHA (12/12/2025, 8:14:43 PM)

After market: 3.87 0 (0%)

3.87

-0.08 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners28.97%
Inst Owner Change-89.93%
Ins Owners3.33%
Ins Owner Change7.3%
Market Cap15.25M
Revenue(TTM)N/A
Net Income(TTM)-37.72M
Analysts45.71
Price Target4.08 (5.43%)
Short Float %2.31%
Short Ratio2.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.52%
Min EPS beat(2)-35%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-3.44%
Min EPS beat(4)-35%
Max EPS beat(4)13.23%
EPS beat(8)6
Avg EPS beat(8)3.86%
EPS beat(12)8
Avg EPS beat(12)3.02%
EPS beat(16)12
Avg EPS beat(16)4.55%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)700%
PT rev (3m)700%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)-821.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-9.68
EYN/A
EPS(NY)-4.94
Fwd EYN/A
FCF(TTM)-13.29
FCFYN/A
OCF(TTM)-13.29
OCFYN/A
SpS0
BVpS6.8
TBVpS6.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.7
Quick Ratio 9.7
Altman-Z -20.52
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.6%
EPS Next Y73.83%
EPS Next 2Y34.35%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

ATHIRA PHARMA INC / ATHA FAQ

What is the fundamental rating for ATHA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATHA.


What is the valuation status for ATHA stock?

ChartMill assigns a valuation rating of 1 / 10 to ATHIRA PHARMA INC (ATHA). This can be considered as Overvalued.


Can you provide the profitability details for ATHIRA PHARMA INC?

ATHIRA PHARMA INC (ATHA) has a profitability rating of 0 / 10.


Can you provide the financial health for ATHA stock?

The financial health rating of ATHIRA PHARMA INC (ATHA) is 6 / 10.


What is the expected EPS growth for ATHIRA PHARMA INC (ATHA) stock?

The Earnings per Share (EPS) of ATHIRA PHARMA INC (ATHA) is expected to grow by 73.83% in the next year.